|
|
 Previous Article | Table of Contents | Next Article 
RAPID COMMUNICATION
In Vivo Expression of B7-1 and B7-2 By Follicular Lymphoma Cells Can Prevent Induction of T-Cell Anergy But Is Insufficient to Induce Significant T-Cell Proliferation
David M. Dorfman,
Joachim L. Schultze,
Aliakbar Shahsafaei,
Sabine Michalak,
John G. Gribben,
Gordon J. Freeman,
Geraldine S. Pinkus, and
Lee M. Nadler
From the Department of Pathology, Brigham and Women's Hospital and the Department of Adult Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Expression of B7 family costimulatory molecules on B cells defines their capacity to function as antigen presenting cells (APCs). B cells that do not express B7 costimulatory molecules induce T-cell tolerance. Therefore, the expression of B7 costimulatory molecules on malignant B cells might be critical for their recognition by anti-tumor-specific T cells. Here we show that virtually all germinal center (GC)-derived B-cell lymphomas including follicular lymphoma (FL) and diffuse large cell lymphoma, but not mantle cell lymphoma or small lymphocytic lymphomas (SLL/CLL), express B7-1 (CD80) and B7-2 (CD86) on their cell surface in situ, although at extremely low levels. Despite their expression of low levels of B7-1 and B7-2, FL cells could not induce significant allogeneic T-cell proliferation. However, B7 costimulatory molecules on FL appeared to be functional because they were capable of increasing T-cell proliferation of preactivated T cells in a secondary allogeneic mixed lymphocyte response. Moreover, low B7 expression was sufficient to prevent the induction of alloantigen-specific anergy in vitro. Therefore, we postulate that whereas low-level expression of B7 is not sufficient to initiate a productive antilymphoma T-cell response, it might be sufficient to prevent T-cell tolerance in vivo.
Blood, Vol. 90 No. 11 (December 1), 1997:
pp. 4297-4306
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. A. Chanan-Khan and B. D. Cheson
Lenalidomide for the Treatment of B-Cell Malignancies
J. Clin. Oncol.,
March 20, 2008;
26(9):
1544 - 1552.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Martin, R. R. Furman, M. Coleman, and J. P. Leonard
Phase I to III Trials of Anti B Cell Therapy in Non Hodgkin's Lymphoma
Clin. Cancer Res.,
September 15, 2007;
13(18):
5636s - 5642s.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Leonard, J. Friedberg, A Younes, D Fisher, L. Gordon, J Moore, M Czuczman, T Miller, P Stiff, B. Cheson, et al.
A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma
Ann. Onc.,
July 1, 2007;
18(7):
1216 - 1223.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Alvaro, M. Lejeune, M.-T. Salvado, C. Lopez, J. Jaen, R. Bosch, and L. E. Pons
Immunohistochemical Patterns of Reactive Microenvironment Are Associated With Clinicobiologic Behavior in Follicular Lymphoma Patients
J. Clin. Oncol.,
December 1, 2006;
24(34):
5350 - 5357.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Anichini, R. Mortarini, L. Romagnoli, P. Baldassari, A. Cabras, C. Carlo-Stella, A. M. Gianni, and M. Di Nicola
Skewed T-cell differentiation in patients with indolent non-Hodgkin lymphoma reversed by ex vivo T-cell culture with {gamma}c cytokines
Blood,
January 15, 2006;
107(2):
602 - 609.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Czuczman, A. Thall, T. E. Witzig, J. M. Vose, A. Younes, C. Emmanouilides, T. P. Miller, J. O. Moore, J. P. Leonard, L. I. Gordon, et al.
Phase I/II Study of Galiximab, an Anti-CD80 Antibody, for Relapsed or Refractory Follicular Lymphoma
J. Clin. Oncol.,
July 1, 2005;
23(19):
4390 - 4398.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Spaner
Amplifying cancer vaccine responses by modifying pathogenic gene programs in tumor cells
J. Leukoc. Biol.,
August 1, 2004;
76(2):
338 - 351.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Niu, G. Cattoretti, and R. Dalla-Favera
BCL6 Controls the Expression of the B7-1/CD80 Costimulatory Receptor in Germinal Center B Cells
J. Exp. Med.,
July 21, 2003;
198(2):
211 - 221.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Krackhardt, S. Harig, M. Witzens, R. Broderick, P. Barrett, and J. G. Gribben
T-cell responses against chronic lymphocytic leukemia cells: implications for immunotherapy
Blood,
June 17, 2002;
100(1):
167 - 173.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Appel, N. P. Seth, L. Gauthier, and K. W. Wucherpfennig
Anergy Induction by Dimeric TCR Ligands
J. Immunol.,
April 15, 2001;
166(8):
5279 - 5285.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. K. Kapsogeorgou, H. M. Moutsopoulos, and M. N. Manoussakis
Functional Expression of a Costimulatory B7.2 (CD86) Protein on Human Salivary Gland Epithelial Cells that Interacts with the CD28 Receptor, but Has Reduced Binding to CTLA4
J. Immunol.,
March 1, 2001;
166(5):
3107 - 3113.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Riemersma, E. S. Jordanova, R. F. J. Schop, K. Philippo, L. H. J. Looijenga, E. Schuuring, and P. M. Kluin
Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites
Blood,
November 15, 2000;
96(10):
3569 - 3577.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. T. Stopeck, A. Gessner, T. P. Miller, E. M. Hersh, C. S. Johnson, H. Cui, Y. Frutiger, and T. M. Grogan
Loss of B7.2 (CD86) and Intracellular Adhesion Molecule 1 (CD54) Expression Is Associated with Decreased Tumor-infiltrating T Lymphocytes in Diffuse B-cell Large-cell Lymphoma
Clin. Cancer Res.,
October 1, 2000;
6(10):
3904 - 3909.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R. T. Costello, F. Mallet, B. Gaugler, D. Sainty, C. Arnoulet, J.-A. Gastaut, and D. Olive
Human Acute Myeloid Leukemia CD34+/CD38- Progenitor Cells Have Decreased Sensitivity to Chemotherapy and Fas-induced Apoptosis, Reduced Immunogenicity, and Impaired Dendritic Cell Transformation Capacities
Cancer Res.,
August 1, 2000;
60(16):
4403 - 4411.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
K. Tarte, X.-G. Zhang, E. Legouffe, C. Hertog, M. Mehtali, J.-F. Rossi, and B. Klein
Induced Expression of B7-1 on Myeloma Cells Following Retroviral Gene Transfer Results in Tumor-Specific Recognition by Cytotoxic T Cells
J. Immunol.,
July 1, 1999;
163(1):
514 - 524.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
